KRAS and neoplasm: In PDAC, mutant KRAS is sustained with a GTP‐binding active form, which acts as a driving factor to activate the tumour‐promoting signalling pathways like PI3K‐AKT, MAPK/ERK, and PLC‐NF‐kB pathways.6